Working… Menu
Trial record 19 of 118 for:    oseltamivir

Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU (ROSII)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01010087
Recruitment Status : Terminated (Patient population no longer available.)
First Posted : November 9, 2009
Last Update Posted : June 10, 2011
Hoffmann-La Roche
Information provided by:
University of Manitoba

Brief Summary:

Primary Objectives:

The primary objective of the trial is to compare the antiviral efficacy of a 10 day course of standard (75 mg bid) and high-dose (225 mg bid) oseltamivir (or equivalent doses in mild-moderate renal failure) in the treatment of severe influenza infections.

The hypothesis is that high dose oseltamivir will increase the proportion of patients with negative reverse transcriptase (RT)-PCR detection of influenza viral RNA (and viral culture, at selected sites) at Day 5 post-treatment.

An important secondary objective of the trial, which reflects the main clinical objective, is to determine the difference in the numbers of ventilator days between the standard-dose and high-dose groups

Condition or disease Intervention/treatment Phase
Influenza A Virus Drug: Oseltamivir Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blinded Controlled Trial Comparing High vs Standard Dose Oseltamivir in Severe, Influenza Infection in ICU. "ROSII Study"
Study Start Date : November 2009
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot
Drug Information available for: Oseltamivir

Arm Intervention/treatment
Active Comparator: Standard Oseltamivir dose 75 mg bid
Standard dosing
Drug: Oseltamivir
standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
Other Name: Tamiflu

Experimental: High Dose Oseltamivir arm 225mg bid
High dose arm of the study
Drug: Oseltamivir
standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
Other Name: Tamiflu

Primary Outcome Measures :
  1. Negative reverse transcriptase (RT)-PCR detection of viral RNA in nasopharyngeal and tracheal aspirate (intubated) or oropharyngeal (non-intubated) samples at Day 5 among patients who require ICU admission due to respiratory distress. [ Time Frame: Day 5 on study ]

Secondary Outcome Measures :
  1. Ventilator days up to 60 d (main clinical endpoint), [ Time Frame: 60 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients age 12 and older and 45 kg or more
  2. Suspected or confirmed influenza (Appendix A)
  3. Requirement for ICU admission due to respiratory distress or critical illness defined as one of:

    1. Inspired oxygen need of >50% for at least 4 hours (For FiO2 for non-intubated patients see Appendix B)
    2. mechanical ventilation
    3. Patient is receiving inotrope or vasopressor
  4. Negative b-HCG test or negative bedside urine test pending a confirmatory b-HCG test for pregnancy in women of childbearing age (12-60 years of age) will allow study entry

Exclusion Criteria:

  1. Inability to obtain consent
  2. Patients receiving more than two doses of 150 mg or higher oseltamivir in 36 hours before study entry
  3. Patients having received more than 3 doses of 75 mg oseltamivir immediately in 36 hours before study entry
  4. Age less than 12 years, or age <16 and weight less than 45 kg
  5. Unlikely to absorb enteral study drug (e.g. patients with partial or complete mechanical bowel obstruction, intestinal ischemia, infarction, and short bowel syndrome)
  6. Known allergy or hypersensitivity to oseltamivir
  7. Pregnancy or breast feeding
  8. Previous enrollment in current study
  9. Concurrent involvement in an RCT examining an antiviral agent including other neuraminidase inhibitors, interferon-a and/or ribavirin
  10. Chronic renal failure requiring chronic hemodialysis
  11. Severe chronic liver disease (Child-Pugh Score 11-15)
  12. Anticipated death within 24 hours as judged by attending physician or local PI
  13. Patient carrying "do not intubate" order (a "no CPR" or "no defibrillate" or "no chest compressions" order alone is allowed)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01010087

Layout table for location information
Canada, Manitoba
Winnipeg Regional Health Authority; Health Sciences Centre
Winnipeg, Manitoba, Canada, R3E 0Z3
Sponsors and Collaborators
University of Manitoba
Hoffmann-La Roche
Layout table for investigator information
Principal Investigator: Anand Kumar, MD University of Manitoba

Layout table for additonal information
Responsible Party: Anand Kumar MD, Winnipeg Regional Health Authority; Health Sciences Centre Identifier: NCT01010087     History of Changes
Other Study ID Numbers: 133312
First Posted: November 9, 2009    Key Record Dates
Last Update Posted: June 10, 2011
Last Verified: June 2011
Keywords provided by University of Manitoba:
patients admitted to ICU
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action